COVID-19 Bill and Melinda Gates Foundation

Together with life science companies around the world, we are joining the COVID-19 Therapeutics Accelerator of the Bill and Melinda Gates Foundation to fight the pandemic. The collaboration aims to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19. Boehringer Ingelheim will contribute its historic molecules, which the Accelerator will be testing. To identify candidate compounds, the Accelerator will take a three-pronged approach: testing approved drugs for activity against COVID-19, screening compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.